The Efficacy and Safety of Temozolomide in SDH-deficient GIST

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 28, 2023

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2027

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

Temozolomide capsule

Temozolomide 200 mg/m2 is administered orally for 1-5 days of each cycle, and then canceled for 23 days (a total of 28 days is 1 cycle)

Trial Locations (1)

RECRUITING

Asan Medical Center, University of Ulsan College of Medicine, Seoul